US 12,233,166 B2
Extended release compositions comprising pyridostigmine
Siva Ram Kiran Vaka, Piscataway, NJ (US); Dipen Desai, Basking Ridge, NJ (US); Wantanee Phuapradit, Lewes, DE (US); Navnit H Shah, Monmouth Junction, NJ (US); and Namdev B. Shelke, Hillsborough, NJ (US)
Assigned to Amneal Complex Products Research LLC, Bridgewater, NJ (US)
Filed by AMNEAL COMPLEX PRODUCTS RESEARCH LLC, Bridgewater, NJ (US)
Filed on Feb. 9, 2024, as Appl. No. 18/437,420.
Application 18/437,420 is a continuation of application No. 18/136,916, filed on Apr. 20, 2023, granted, now 11,911,515.
Application 18/136,916 is a continuation of application No. 17/550,117, filed on Dec. 14, 2021, granted, now 11,666,536, issued on Jun. 6, 2023.
Application 17/550,117 is a continuation of application No. 16/609,397, granted, now 11,229,606, issued on Jan. 25, 2022, previously published as PCT/US2019/037795, filed on Jun. 18, 2019.
Claims priority of provisional application 62/826,402, filed on Mar. 29, 2019.
Claims priority of provisional application 62/725,024, filed on Aug. 30, 2018.
Prior Publication US 2024/0299305 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/28 (2006.01); A61K 9/50 (2006.01); A61K 31/4425 (2006.01)
CPC A61K 9/2886 (2013.01) [A61K 9/5042 (2013.01); A61K 9/5073 (2013.01); A61K 31/4425 (2013.01); A61K 9/2866 (2013.01)] 20 Claims
 
1. A gastroretentive dosage form comprising a core, and a permeable elastic membrane comprising at least one orifice and surrounding the core,
wherein the core comprises pyridostigmine or a pharmaceutically acceptable salt thereof,
wherein the permeable elastic membrane comprises a copolymer based on ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride, and
wherein the copolymer is present in an amount of from about 70 wt % to about 95 wt %, based on the total weight of the membrane.